Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUC-MSC transfusion for acute-on-chronic liver failure
ChiCTR2100050852Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Nov 2021
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of human umbilical cord derived mesenchymal stem cells in acute-on-chronic liver failure (ACLF) and Subfulminant Hepatitis, sponsored by Xijing Hospital. Primary endpoints: Adverse events, Dose-limiting toxicity and 2 more. Started Nov 2021; status: recruiting.
02
Drugs
human umbilical cord derived mesenchymal stem cells
03
Conditions
acute-on-chronic liver failure (ACLF)Subfulminant Hepatitis
Beyond the preview
Go deeper on ChiCTR2100050852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050852.